667sek
-2,1 %
Date:2024-05-03Time:10:42:25Latest report:Q4-2023List:Small CapTicker:SYNACT
Market Cap:278 msekEnterprise Value:216 msekNet Sales:- msekEarnings:-215,8 msekEmployees:0ISIN:SE0008241491

Ratios

10-year key figure history for SynAct Pharma turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for SynAct Pharma with index and moving average MA50 and MA200.

Stockprice:6,67
MA50:7,29
MA200:23,48
Price/MA200:-71,4 %
RSI (14):43,1
Price/MA50:-7,9 %

Description

SynAct Pharma AB is a clinical-stage biotech company focused on resolving inflammation through selective activation of the melanocortin system. The company has a platform technology based on a new class of drug candidates that target acute exacerbations in chronic inflammatory diseases with the primary aim of stimulating natural healing mechanisms. AP1189, the company's lead drug candidate, is being evaluated in three Phase 2 clinical programs regarding rheumatoid arthritis, idiopathic membranous glomerulonephritis and virus-induced respiratory failure.

Biotechnology